Status: Recruiting
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
Participants needed: 125
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Remix TherapeuticsUpdated: Jun 24, 2026Locations: 9
Eligibility criteria
Be able to provide informed consent. [+19]
Known hypersensitivity or contraindication to any component of REM-422 or to dru... [+19]